Additional drugs that act on the IL4/13 axis are under current investigation in CRS, including; GR 1802, an anti-IL-4 receptor (NCT06516302 – phase 3, not yet recruiting); “611” an anti-IL4 receptor (NCT06639295 – phase 3, not yet recruiting); and lebrikizumab, an IL-13 inhibitor (NCT06338995 – phase 3, recruiting). This evidence concerns the gene IL4 and congenital rubella syndrome.